Cardiometabolic Risk, Part 1: Chemotherapy and Radiotherapy - Old Foes Still Threatening Cancer Survivors?
Journal
Frontiers of hormone research
ISSN: 1662-3762
Titre abrégé: Front Horm Res
Pays: Switzerland
ID NLM: 0320246
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
10
2020
accepted:
19
12
2020
pubmed:
9
2
2021
medline:
11
3
2022
entrez:
8
2
2021
Statut:
ppublish
Résumé
Long-term cancer survivors are at high risk of developing cardiac complications from the treatments, both systemic agents and thoracic irradiation, received to cure the primary tumor. Modern advances, particularly in the field of radiotherapy, aim to reduce the risk of cardiovascular disease. Also, new diagnostic tools increasingly improve their efficacy in early detection of the preclinical treatment-induced cardiac damage. In this review, we summarize the mechanisms of radiotherapy- and chemotherapy-induced cardiac injury, the available clinical data, the strategies to mitigate cardiac exposure with modern radiotherapy and the current diagnostic tools for an early detection and prompt management of these complications in long-term cancer survivors.
Identifiants
pubmed: 33556955
pii: 000513921
doi: 10.1159/000513921
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
115-129Informations de copyright
© 2021 S. Karger AG, Basel.